Fewer Regulatory Barriers in Europe Benefit Companion Diagnostics Sector
By LabMedica International staff writers Posted on 01 Jul 2014 |
The growth in personalized medicine has led to increased interest in companion diagnostics (CDx) tests or tests that match the right therapy to the patient.
Over the past few years, market participants have been entering pharmaceutical and diagnostic partnerships in order to develop and commercialize CDx tests for drugs that already exist in the market. Currently, the oncology segment is the main focus in the CDx market, but it is envisioned that non-oncology segments—such as central nervous system, infectious disease, and cardiovascular conditions—will receive a great deal of attention in the years to come.
A new analysis from Frost & Sullivan (London, United Kingdom) finds that the CDx market earned revenues of USD 457 million in 2013 and estimates this to reach USD 1,295.1 million in 2018, at a compound annual growth rate of 23.2 %. The study covers the oncology areas such as breast cancer, colorectal cancer, and lung cancer panel segments and non-oncology areas such as infectious, CNS, and cardio vascular diseases for Western Europe, including the United Kingdom, Germany, Italy, France, Spain, Benelux, and Scandinavia.
Frost & Sullivan Healthcare senior industry analyst Divyaa Ravishankar commented, “Limited regulatory barriers for drug and diagnostic combination products, which the current in vitro diagnostic directive classifies under the low-risk category, are easing market access. As nearly all diagnostic tests in Europe belong to the low risk category, they are exempt from pre-market evaluation. As a result, manufacturers tend to self-assess conformity, self-certify CDx products, and CE mark them before sale in the European market. This laid-back process has resulted in a higher rate of approval of new CDx tests and products.”
Intense competition from laboratory-developed test (LDT) manufacturers—who offer tests through reference laboratories across Europe and the rest of the world—is hampering market growth. The entry of foreign LDT companies into the market through partnership with local companies, as well as the inclination of companies across Western Europe to promote the use of LDT over manufactured and approved CDx tests, are exacerbating the situation.
The variation in reimbursement policies across Western Europe is creating an unpredictable environment, adversely affecting the uptake of new CDx test technologies. Along with the lack of a robust coverage and payment process, this is denting the prospects of CDx manufacturers in the region.
Related Links:
Frost & Sullivan
Over the past few years, market participants have been entering pharmaceutical and diagnostic partnerships in order to develop and commercialize CDx tests for drugs that already exist in the market. Currently, the oncology segment is the main focus in the CDx market, but it is envisioned that non-oncology segments—such as central nervous system, infectious disease, and cardiovascular conditions—will receive a great deal of attention in the years to come.
A new analysis from Frost & Sullivan (London, United Kingdom) finds that the CDx market earned revenues of USD 457 million in 2013 and estimates this to reach USD 1,295.1 million in 2018, at a compound annual growth rate of 23.2 %. The study covers the oncology areas such as breast cancer, colorectal cancer, and lung cancer panel segments and non-oncology areas such as infectious, CNS, and cardio vascular diseases for Western Europe, including the United Kingdom, Germany, Italy, France, Spain, Benelux, and Scandinavia.
Frost & Sullivan Healthcare senior industry analyst Divyaa Ravishankar commented, “Limited regulatory barriers for drug and diagnostic combination products, which the current in vitro diagnostic directive classifies under the low-risk category, are easing market access. As nearly all diagnostic tests in Europe belong to the low risk category, they are exempt from pre-market evaluation. As a result, manufacturers tend to self-assess conformity, self-certify CDx products, and CE mark them before sale in the European market. This laid-back process has resulted in a higher rate of approval of new CDx tests and products.”
Intense competition from laboratory-developed test (LDT) manufacturers—who offer tests through reference laboratories across Europe and the rest of the world—is hampering market growth. The entry of foreign LDT companies into the market through partnership with local companies, as well as the inclination of companies across Western Europe to promote the use of LDT over manufactured and approved CDx tests, are exacerbating the situation.
The variation in reimbursement policies across Western Europe is creating an unpredictable environment, adversely affecting the uptake of new CDx test technologies. Along with the lack of a robust coverage and payment process, this is denting the prospects of CDx manufacturers in the region.
Related Links:
Frost & Sullivan
Latest Industry News
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance